Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel ...
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...
In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a major target in cancer immunotherapy. Now, Dr. Ishida and colleagues ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study ...
Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, ...
Prognostic value of dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. First-in-human phase I, ...
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results